Y10S 530/867
Involving immunoglobulin or antibody produced via recombinant dna technology
Official title: involving immunoglobulin or antibody produced via recombinant dna technology
Y10S530/867 (Involving immunoglobulin or antibody produced via recombinant dna technology) appears on 124 US grants and 50 published applications in this corpus.
Search patents in Y10S- Granted patents
- 124
- Published applications
- 50
- Assignees
- 74
- Inventors
- 206
- Latest grant
- 29 Mar 2016
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 1 | 0 |
| 1990 | 5 | 0 |
| 1991 | 1 | 0 |
| 1992 | 4 | 0 |
| 1993 | 2 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 8 | 0 |
| 1997 | 9 | 0 |
| 1998 | 15 | 0 |
| 1999 | 11 | 0 |
| 2000 | 5 | 0 |
| 2001 | 5 | 1 |
| 2002 | 8 | 4 |
| 2003 | 10 | 8 |
| 2004 | 6 | 3 |
| 2005 | 1 | 5 |
| 2006 | 2 | 2 |
| 2007 | 4 | 3 |
| 2008 | 4 | 4 |
| 2009 | 3 | 5 |
| 2010 | 4 | 5 |
| 2011 | 4 | 1 |
| 2012 | 5 | 2 |
| 2013 | 0 | 0 |
| 2014 | 2 | 1 |
| 2015 | 0 | 0 |
| 2016 | 1 | 3 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 1 |
| 2022 | 0 | 0 |
| 2023 | 0 | 1 |
| 2024 | 0 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function29 Mar 2016US 9,296,820 B2Roche Glycart AG
- Antigen binding molecules with increased Fc receptor binding affinity and effector function11 Nov 2014US 8,883,980 B2Roche Glycart AG
- Avian derived antibodies26 Aug 2014US 8,815,242 B2Synageva BioPharma Corp.
- Methods for treating B-cell lymphoma by administering an anti-CD20 antibody11 Dec 2012US 8,329,181 B2Regeneron Pharmaceuticals, Inc.
- Compositions, methods and kits relating to anti-platelet autoantibodies and inhibitors thereof10 Jul 2012US 8,216,581 B2The Trustees of the University of Pennsylvania
- Antigen binding molecules with increased fc receptor binding affinity and effector function12 Sep 2024US 2024/0301079 A1Roche Glycart AG
- Antigen binding molecules with increased fc receptor binding affinity and effector function6 Jul 2023US 2023/0212303 A1Roche Glycart AG
- Antigen binding molecules with increased fc receptor binding affinity and effector function7 Jan 2021US 2021/0002382 A1Roche Glycart AG
- Antigen binding molecules with increased fc receptor binding affinity and effector function17 Mar 2016US 2016/0075793 A1Roche Glycart AG
- Antigen binding molecules with increased fc receptor binding affinity and effector function17 Mar 2016US 2016/0075794 A1Roche Glycart AG
Most cited
By later US patents
- Recombinant immunoglobin preparations4,785US 4,816,567 AGenentech, Inc. · 1989
- Single polypeptide chain binding molecules2,454US 4,946,778 AGenex Corporation · 1990
- Production of chimeric antibodies - a combinatorial approach1,367US 5,565,332 ACambridge Antibody Technology Limited · 1996
- Methods for producing members of specific binding pairs893US 5,969,108 ACambridge Antibody Technology Limited · 1999
- Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma744US 5,736,137 AIDEC Pharmaceuticals Corporation · 1998